1. Home
  2. DDC vs APLM Comparison

DDC vs APLM Comparison

Compare DDC & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DDC
  • APLM
  • Stock Information
  • Founded
  • DDC 2012
  • APLM 2016
  • Country
  • DDC United States
  • APLM United States
  • Employees
  • DDC N/A
  • APLM N/A
  • Industry
  • DDC Metal Mining
  • APLM Blank Checks
  • Sector
  • DDC Basic Materials
  • APLM Finance
  • Exchange
  • DDC Nasdaq
  • APLM Nasdaq
  • Market Cap
  • DDC 12.7M
  • APLM 12.3M
  • IPO Year
  • DDC 2023
  • APLM N/A
  • Fundamental
  • Price
  • DDC $0.22
  • APLM $7.02
  • Analyst Decision
  • DDC Strong Buy
  • APLM Strong Buy
  • Analyst Count
  • DDC 1
  • APLM 2
  • Target Price
  • DDC $3.00
  • APLM $425.00
  • AVG Volume (30 Days)
  • DDC 560.5K
  • APLM 7.4K
  • Earning Date
  • DDC 01-01-0001
  • APLM 03-04-2025
  • Dividend Yield
  • DDC N/A
  • APLM N/A
  • EPS Growth
  • DDC N/A
  • APLM N/A
  • EPS
  • DDC N/A
  • APLM N/A
  • Revenue
  • DDC $32,882,772.00
  • APLM $2,101,000.00
  • Revenue This Year
  • DDC N/A
  • APLM N/A
  • Revenue Next Year
  • DDC N/A
  • APLM N/A
  • P/E Ratio
  • DDC N/A
  • APLM N/A
  • Revenue Growth
  • DDC 18.16
  • APLM 70.54
  • 52 Week Low
  • DDC $0.12
  • APLM $6.38
  • 52 Week High
  • DDC $2.53
  • APLM $80.50
  • Technical
  • Relative Strength Index (RSI)
  • DDC 62.44
  • APLM 37.88
  • Support Level
  • DDC $0.19
  • APLM $6.70
  • Resistance Level
  • DDC $0.25
  • APLM $7.60
  • Average True Range (ATR)
  • DDC 0.02
  • APLM 0.70
  • MACD
  • DDC 0.01
  • APLM -0.03
  • Stochastic Oscillator
  • DDC 62.72
  • APLM 22.30

About DDC DDC Enterprise Limited

DDC Enterprise Ltd is a content driven consumer brand offering easy, convenient ready-to-heat , ready-to-cook and plant-based meal products i.e. meal products consisting largely or solely of vegetables, fruits, grains and other foods derived from plant-based protein, rather than animal protein) while promoting healthier lifestyle choices to Millennial and Generation Z customer-base. It is also engaged in the provision of advertising services and the operation of experience stores to offer cooking classes.

About APLM Apollomics Inc.

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

Share on Social Networks: